Literature DB >> 15674359

Phenotypic and functional relationship between adult T-cell leukemia cells and regulatory T cells.

Y Matsubara, T Hori, R Morita, S Sakaguchi, T Uchiyama.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15674359     DOI： 10.1038/sj.leu.2403628

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  12 in total

1.  Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans.

Authors:  Daisuke Sugiyama; Hiroyoshi Nishikawa; Yuka Maeda; Megumi Nishioka; Atsushi Tanemura; Ichiro Katayama; Sachiko Ezoe; Yuzuru Kanakura; Eiichi Sato; Yasuo Fukumori; Julia Karbach; Elke Jäger; Shimon Sakaguchi
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-14       Impact factor: 11.205

Review 2.  Are increased Foxp3+ regulatory T cells responsible for immunosuppression during HTLV-1 infection? Case reports and review of the literature.

Authors:  Nicolas Barros; Fernando Woll; Luis Watanabe; Martin Montes
Journal:  BMJ Case Rep       Date:  2012-11-27

3.  FOXP3 can modulate TAL1 transcriptional activity through interaction with LMO2.

Authors:  V Fleskens; M Mokry; A M van der Leun; S Huppelschoten; C E G M Pals; J Peeters; S Coenen; B A Cardoso; J T Barata; J van Loosdregt; P J Coffer
Journal:  Oncogene       Date:  2015-12-21       Impact factor: 9.867

4.  Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3.

Authors:  Monika Kasprzycka; Michal Marzec; Xiaobin Liu; Qian Zhang; Mariusz A Wasik
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-09       Impact factor: 11.205

5.  Expression of T-plastin, FoxP3 and other tumor-associated markers by leukemic T-cells of cutaneous T-cell lymphoma.

Authors:  Elisabetta Capriotti; Eric C Vonderheid; Christopher J Thoburn; Mariusz A Wasik; David W Bahler; Allan D Hess
Journal:  Leuk Lymphoma       Date:  2008-06

6.  Gamma c-signaling cytokines induce a regulatory T cell phenotype in malignant CD4+ T lymphocytes.

Authors:  Monika Kasprzycka; Qian Zhang; Agnieszka Witkiewicz; Michal Marzec; Magdalena Potoczek; Xiaobin Liu; Hong Yi Wang; Michael Milone; Samik Basu; Joanne Mauger; John K Choi; J Todd Abrams; J Steven Hou; Alain H Rook; Eric Vonderheid; Anders Woetmann; Niels Odum; Mariusz A Wasik
Journal:  J Immunol       Date:  2008-08-15       Impact factor: 5.422

7.  Switching and loss of cellular cytokine producing capacity characterize in vivo viral infection and malignant transformation in human T- lymphotropic virus type 1 infection.

Authors:  Huseini Kagdi; Maria Antonietta Demontis; Juan Carlos Ramos; Graham P Taylor
Journal:  PLoS Pathog       Date:  2018-02-14       Impact factor: 6.823

8.  Animal models on HTLV-1 and related viruses: what did we learn?

Authors:  Hiba El Hajj; Rihab Nasr; Youmna Kfoury; Zeina Dassouki; Roudaina Nasser; Ghada Kchour; Olivier Hermine; Hugues de Thé; Ali Bazarbachi
Journal:  Front Microbiol       Date:  2012-09-21       Impact factor: 5.640

9.  The combination of arsenic, interferon-alpha, and zidovudine restores an "immunocompetent-like" cytokine expression profile in patients with adult T-cell leukemia lymphoma.

Authors:  Ghada Kchour; Rahim Rezaee; Reza Farid; Akram Ghantous; Houshang Rafatpanah; Mahdi Tarhini; Mohamad-Mehdi Kooshyar; Hiba El Hajj; Fadwa Berry; Mohamad Mortada; Roudaina Nasser; Abbas Shirdel; Zeina Dassouki; Mohamad Ezzedine; Hossein Rahimi; Ardeshir Ghavamzadeh; Hugues de Thé; Olivier Hermine; Mahmoud Mahmoudi; Ali Bazarbachi
Journal:  Retrovirology       Date:  2013-08-20       Impact factor: 4.602

10.  Human T-cell Leukemia Virus Type I Associated with an Increased Risk of Primary Malignant Neoplasm.

Authors:  Aya Nakaya; Shinya Fujita; Atsushi Satake; Takahisa Nakanishi; Yoshiko Azuma; Yukie Tsubokura; Akiko Konishi; Masaaki Hotta; Hideaki Yoshimura; Kazuyoshi Ishii; Tomoki Ito; Shosaku Nomura
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-04-20       Impact factor: 2.576
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.